DSM Licenses c-LEcta Screening Technology

DSM Pharmaceutical Products has entered a license agreement with c-LEcta GmbH for its alcohol dehydrogenases screening technology for enzyme screening programs and development of sustainable manufacturing routes for pharmaceutical active ingredients and intermediates.

The technology platform has been used by c-LEcta for the identification and optimization of biocatalysts, resulting in a collection of several hundred enzymes and qualified enzyme mutants. DSM will also provide commercialization of sustainable enzyme-based manufacturing routes developed by its InnoSyn route scouting services for c-LEcta.

Dr. Oliver May, business manager for DSM, said, “This agreement further broadens our alcohol dehydrogenase platform which we set up for rapid screening programs for our customers and the development of cost efficient production of a large spectrum of chiral secondary alcohols.”

Dr. Thomas Greiner-Stoffele, chief scientific officer for c-LEcta, added, “We are pleased to have this cooperation with DSM which will give us very useful benchmarks for our alcohol dehydrogenase collection. We are constantly expanding our biocatalysts collection with unique enzymes from biodiversity and engineering projects to provide solutions also for challenging targets.”